CARPENTER, RANDALL L.,ROBERTS, KATHRYN,BEAR, MARK F.
申请号：
CA2670116
公开号：
CA2670116C
申请日:
2007.11.21
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-am inobutyric acid agonists and/or Ml muscarinic rreceptor antagonists. The gamma-am inobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and Ml muscarinic receptor antagonists in methods of treating humans.
